Last reviewed · How we verify
LACTASE
LACTASE is an enzymatic product currently on the market, designed to break down lactose into glucose and galactose, addressing lactose intolerance. The key strength of LACTASE lies in its well-established mechanism and market presence, with a key composition patent expiring in 2028, providing a period of exclusivity. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | LACTASE |
|---|---|
| Modality | Enzyme |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Lactase Enzyme Supplementation for Growth and Feeding Tolerance in Preterm Infants (NA)
- A Phase I Study of Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis (PHASE1)
- Galactol® Enzyme Supplement for Post-Prandial Abdominal Bloating in Irritable Bowel Syndrome (NA)
- Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates (NA)
- Milk for Diabetes Prevention (NA)
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis (PHASE1,PHASE2)
- Lactase-Assisted Control Trial On Weight GAin in INfants. (NA)
- Comparison of the Effectiveness of Oral Lactase Enzyme and Lactose Free Formula (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LACTASE CI brief — competitive landscape report
- LACTASE updates RSS · CI watch RSS